Tumor-associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease patterns

Clinical and Experimental Metastasis

Volumn 16, Issue 1, 1998, Pages 62-73

  Allgayer, Heike ^a   Babic, Rudolf ^b   Grützner, Klaus Uwe ^a   Beyer, Bianca C M ^a   Tarabichi, Anwar ^a   Schildberg, Friedrich Wilhelm ^a   Heiss, Markus Maria ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institute of Pathology and Cytology   (Germany)

Author keywords

Gastric cancer; Prognosis; Protease patterns; Tumor associated proteolysis

Indexed keywords

PROTEINASE;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CORRELATION FUNCTION; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; RISK ASSESSMENT; STATISTICAL ANALYSIS; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ENDOPEPTIDASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; PROTEASE INHIBITORS; RISK FACTORS; STATISTICS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031938422     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006564002679     Document Type: Article

References (44)

1. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen P, 1990, Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res, 50, 6827-9.
2. Graeff H, Harheck N, Pache O, Wilhelm O, Jänicke F and Schmitt M, 1992, Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis, 6(Suppl 4), 45-53.
3. Pedersen H, Grondahl-Hansen J, Francis D, et al. 1994, Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54, 120-3.
4. Heiss MM, Babic R, Allgayer H, et al. 1995, Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol, 13, 2084-93.
5. Heiss MM, Babic R, Allgayer H, et al. 1996, The prognostic impact of the urokinase-type plasminogen activator system is associated with tumor differentiation in gastric cancer. Eur J Surg Oncol, 22, 74-7.
6. Jänicke F, Schmitt M, Pache L, et al. 1993, Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treatment, 24, 195-208.
7. Ossowski L, Clunie G, Masucci MT and Blasi, F, 1991, In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J Cell Biol. 115, 1107-12.
8. Blasi F, 1993, Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. BioEssays, 15, 105-11.
9. Dvorak HF, 1986, Tumors: Wounds that do not heal. N Engl J Med, 315, 1650-9.
10. Schmitt M, Jänicke F and Graeff H, 1992, Tumor-associated proteases. Fibrinolysis, 6(Suppl 4), 3-26.
11. Duffy MJ, 1992, The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis, 10, 145-55.
12. Liotta LA, 1986, Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res, 46, 1-7.
13. Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell, 64, 327-36.
14. Schwartz GK, Wang H, Lampen N, Altorki N, Kelsen D and Albino AP, 1994, Defining the invasive phenotype of proximal gastric cancer cells. Cancer, 73, 22-7.
15. Nomura H, Fujimoto N, Seiki M, Mai M and Okada Y, 1996, Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (Gelatinase A) in human gastric carcinomas. Int J Cancer (Pred. Oncol.), 69, 9-16.
16. Nykjaer A, Petersen CM, Moller B, et al. 1992, Purified alpha 2-macroglobulin receptor/LDL receptor related protein binds urokinase-plasminogen activator inhibitor type 1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem, 267, 14543-6.
17. Andreasen PA, Sottrup-Jensen L, Kjoller L, et al. 1994, Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 338, 239-45.
18. Ichinose A, Fujikawa K and Suyama T, 1986, The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem, 261, 3486-9.
19. Moller LB, 1993, Structure and function of the urokinase receptor. Blood Coagulation and Fibrinolysis, 4, 293-303.
20. Goretzki L, Schmitt M, Mann KH, et al. 1992, Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett. 297, 112-18.
21. Tandon AK, Clark GM, Chamness GC, Chirgwin JM and McGuire WL, 1990, Cathepsin D and prognosis in breast cancer. N Engl J Med, 322, 297-302.
22. Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P and Battifora H, 1993, Prognostic significance of immunohistochemical analysis of Cathepsin D in low-stage breast cancer. Cancer, 71, 2756-63.
23. Straight DL, Hassett MA and McKee PA, 1985. Structural and functional characterization of the inhibition of urokinase by α-2-macroglobulin. Biochemistry, 24, 3902-7.
24. Sier CFM, Vespaget HW, Griffionen G, Ganesh S, Vloedgraven HJM and Lamers CBHW, 1993, Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut, 34, 80-5.
25. Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y, 1991, Relationship between plasminogen activators and stomach carcinoma stage. Acta Oncologica, 30, 815-18.
26. Buo L, Meling GI, Karlsrud TS, Johansen HT and Aasen AO, 1995, Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol, 26, 1133-8.
27. Kaplan EL and Meier P, 1958, Nonparametric estimation from incomplete observation. J Am Stat Assoc, 53, 457-81.
28. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR and Howard SV, 1977, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer, 37, 1-39.
29. Co DR, 1972, Regression models and life tables. J Stat Soc (B), 34, 187-220.
30. Dixon WJ, Brown MB, Engelman L, et al. 1985, BMDP statistical software. Berkeley: University of California Press.
31. Matoska J, Wahlstrom T, Vaheri A, Bizik J and Grofova M, 1988, Tumor-associated α-2-macroglobulin in human melanomas. Int J Cancer, 41, 359.
32. McGarvey T, Hussain MM and Stearns ME, 1996. In situ hybridization studies of α-2-macroglobulin receptor and receptor-associated protein in human prostate carcinoma. Prostate, 28, 311-17.
33. Grigioni WF, D'Errico A, Fortunato C, et al. 1994, Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol, 7, 220-5.
34. Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S and Tateishi R, 1995, Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Cancer, 76, 1368-76.
35. Ljungberg B, Grankvist K and Rasmuson T, 1995, Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer, 76, 1435-9.
36. Takai S, Yamamura M, Tanaka K, et al. 1991, Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical staining. Int J Cancer, 48, 20-7.
37. Keohane ME, Hall SW, Vandenberg SR and Gonias SL, 1990, Secretion of α-2-macroglobulin, α-2-antiplasmin, and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture. J Neurosurg, 73, 234-41.
38. Davies B, Miles DW, Happerfield LC, et al. 1993, Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer, 67, 1126-31.
39. Höyhtyä M, Fridman R, Komarek D, et al. 1994, Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer, 56, 500-5.
40. Hollas W, Blasi F and Boyd D, 1991, Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res, 51, 3690-5.
41. Pyke C, Graem N, Ralfkiaer E, et al. 1993, Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res, 53, 1911-15.
42. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J and Dano K, 1991, The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res, 51, 4067-71.
43. Pyke C, Kristensen P, Ralfkiaer E, et al. 1991, Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol, 138, 1059-67.
44. Smorenburg SM, Griffini P, Tiggelman AB, Moorman AF, Boers W and Van Noorden JF, 1996, Alpha-2-macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Hepatology, 23, 560-70.